Cutia Therapeutics Completes Successful Private Placement of New Shares, Raising Funds from Key Investors
Cutia Therapeutics has successfully completed a private placement of new shares under a general mandate. The company announced that a total of 28,904,000 placing shares were successfully placed by the Placing Agents to TruMed Health Innovation Fund LP, Octagon Investments Master Fund LP, and Octagon Private Opportunities Fund II LP at a placing price of HK$8.40 per share. TruMed, an exempted limited partnership incorporated in the Cayman Islands, is a pooled investment fund primarily investing in healthcare equities. This completion marks a significant step for Cutia Therapeutics in raising capital to support its endeavors.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cutia Therapeutics published the original content used to generate this news brief on September 05, 2025, and is solely responsible for the information contained therein.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。